Your browser doesn't support javascript.
loading
Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse.
Ashizawa, Tadashi; Iizuka, Akira; Tanaka, Emiko; Kondou, Ryota; Miyata, Haruo; Maeda, Chie; Sugino, Takashi; Yamaguchi, Ken; Ando, Takayuki; Ishikawa, Yoshinobu; Ito, Mamoru; Akiyama, Yasuto.
Afiliação
  • Ashizawa T; Immunotherapy Division, Shizuoka Cancer Center Research Institute.
  • Iizuka A; Immunotherapy Division, Shizuoka Cancer Center Research Institute.
  • Tanaka E; Immunotherapy Division, Shizuoka Cancer Center Research Institute.
  • Kondou R; Immunotherapy Division, Shizuoka Cancer Center Research Institute.
  • Miyata H; Immunotherapy Division, Shizuoka Cancer Center Research Institute.
  • Maeda C; Immunotherapy Division, Shizuoka Cancer Center Research Institute.
  • Sugino T; Division of Pathology, Shizuoka Cancer Center Hospital.
  • Yamaguchi K; Office of the president, Shizuoka Cancer Center Hospital.
  • Ando T; Shizuoka Institute of the Environment and Hygiene.
  • Ishikawa Y; School of Pharmaceutical Sciences, University of Shizuoka.
  • Ito M; Central Institute for Experimental Animals.
  • Akiyama Y; Immunotherapy Division, Shizuoka Cancer Center Research Institute.
Biomed Res ; 40(6): 243-250, 2019.
Article em En | MEDLINE | ID: mdl-31839668

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antígeno B7-H1 / Receptor de Morte Celular Programada 1 / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Biomed Res Ano de publicação: 2019 Tipo de documento: Article País de publicação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antígeno B7-H1 / Receptor de Morte Celular Programada 1 / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Biomed Res Ano de publicação: 2019 Tipo de documento: Article País de publicação: Japão